AMEVIVE® Pregnancy Registry

Stopped early

Conditions studied: Pregnancy

In brief

This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects. The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Key facts

Study ID

NCT00342862

Run by

Astellas Pharma Inc

People needed

3

Starts

2003-12-01

Expected to finish

2011-12-01

Last updated by the study team

2013-12-11

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Have been exposed to AMEVIVE® within 8 weeks prior to conception or at any time during pregnancy
• Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively)
• Provide verbal consent to participate in the Registry, and
• Verbally provide the contact information for herself, her healthcare provider (HCP), and the infant's HCP (if applicable)

You may not qualify if…

• None

Where it is running

• INC Research — Wilmington, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.